That’s why we’re building for the future in Lengnau and around the world to meet growing demand and bring more therapies to more patients.
September 22, 2016
By Uwe E. Jocham
These are exciting times at CSL Behring, as we expand our infrastructure to keep pace with the increasing demand for new innovations that address unmet medical needs or enhance current treatments.
We are currently building for the future in Lengnau, Switzerland, where we are constructing a state-of-the-art recombinant manufacturing facility. The foundation stone of the new structure was laid in May. With this production site, CSL Behring is creating a new product family based on state-of-the-art technology.
The plant will manufacture and globally market three new recombinant coagulation factors: recombinant Factor IX Fusion Protein for patients with hemophilia B, recombinant Factor VIII-Single Chain to treat hemophilia A, and a recombinant Factor VIIa-Fusion Protein treat hemophilia patients with inhibitors.
“If we think about patients every day and do the right things for them, the rest will take care of itself.”
September 13, 2016
By Christopher Florentz
This summer’s World Federation of Hemophilia Congress got off to a fast start with CSL Behring’s coagulation team eager to meet with patients and healthcare providers and discuss their needs and how we can meet them.
The level of excitement among the CSL Behring’s team was palpable, as CSL CEO and Managing Director Paul Perreault kicked things off at the start of the Congress by reinforcing to them the importance of maintaining focus on what matters most:
“If we think about patients every day and do the right things for them, the rest will take care of itself. We began with the promise to produce much needed medicines for the people of Australia. Today we are bringing medicines to the world.”
August 23, 2016
By Toby Simon, MD
Zika virus has been widely reported in the news during the past year, so much so that a number of athletes chose to stay home rather than compete in the Olympics in Rio de Janeiro and risk infection. We therefore understand that patients treated with our plasma derived products want to be certain they are not at risk for infection with Zika virus through their treatment with our products.
Infection with the Zika virus generally results in no symptoms, but 20% or more of individuals infected will have a mild illness of 5 to 7 days with fever, rash, headache, and discomfort in their hands, wrists, and ankles. This virus has also been associated with Guillain-Barre syndrome, a self-limited disease of the nervous system that can be serious.
Most of the public health concern relates to infection in pregnant women, because microcephaly (incomplete brain development) and other fetal defects have resulted from infection with this virus. The virus is spread by mosquito bites, but there is evidence of transmission through sexual contact and blood transfusion. The virus has been most common in tropical areas. The epidemic is severe in Puerto Rico and has emerged in the United States through both travel and in the last month from local mosquito transmissions in south Florida.
“Part of me was slightly ashamed that I had hemophilia growing up. It was something I tried to hide.”
August 4, 2016
New father and hemophilia A patient Tim Grams is an outdoor adventurer. See how Tim isn’t letting this hereditary blood disorder keep him from enjoying the Colorado outdoors, including hiking Dinosaur Ridge and mountain biking at Red Rocks Park. Click the image below to watch the video.
The science of pharmacometrics is changing the way some therapeutic recommendations are expedited around the world.
By Jagdev Sidhu, PhD and Michael Tortorici, PhD
At CSL Behring, we have a keen understanding of the difference that accelerated access to vital therapies as well as therapeutic recommendations can mean for patients with rare and serious medical disorders.
Pharmacometrics offers an exciting alternative to traditional clinical trials in certain instances by allowing the approval of more flexible usage of therapeutic products without a clinical trial. For the majority of patients with a rare disease who are on chronic therapies, this is good news indeed.
The approval of medicines and their therapeutic options takes place in a rigorous and uncompromising regulatory environment in which the wellbeing of patients is the main priority. At the same time, regulators around the world are increasingly engaging with the pharmaceutical companies to advance methodologies, such as the use of pharmacometrics that bring innovation to the drug development process.